Your browser doesn't support javascript.
loading
Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis.
Hirose, Satoshi; Hara, Makoto; Kamei, Satoshi; Dalmau, Josep; Nakajima, Hideto.
Afiliação
  • Hirose S; Division of Neurology, Department of Medicine, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicyo, Itabashi-ku, Tokyo, 173-8610, Japan.
  • Hara M; Division of Neurology, Department of Medicine, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicyo, Itabashi-ku, Tokyo, 173-8610, Japan. hara.makoto@nihon-u.ac.jp.
  • Kamei S; Division of Neurology, Department of Medicine, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicyo, Itabashi-ku, Tokyo, 173-8610, Japan.
  • Dalmau J; Department of Neurology, Center for Neuro-infection, Ageo Central General Hospital, Saitama, Japan.
  • Nakajima H; Neuroimmunology Program, Hospital Clinic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
J Neurol ; 269(5): 2486-2492, 2022 May.
Article em En | MEDLINE | ID: mdl-34613453
ABSTRACT

OBJECTIVE:

The main syndrome of anti-N-methyl-D-aspartate receptor encephalitis (NMDARE) is well-characterized, however, the difference in main symptoms between the initial episode and relapses and patient-oriented long-term outcomes has not been previously described.

METHODS:

To investigate the difference in syndrome symptoms between episodes and patient-oriented outcomes, we administered a structured questionnaire survey for the patients with anti-NMDARE or their family members. From the answers, we analyzed the frequency of main symptoms (e.g., prodromes, abnormal behaviors, memory deficit, speech disorders, involuntary movements, hypo-ventilation) between episodes and patient-oriented outcomes that included the recovery rate for return to previous work or school.

RESULTS:

Fifty-six patients were enrolled, and 14 (25%) showed clinical relapse. Details of symptoms at relapse were obtained from 11 patients. Prodrome (27% vs. 96%, p < 0.001), decreased level of consciousness (55% vs. 88%, p = 0.021), seizures (36% vs. 77%, p = 0.012), and involuntary movements (27% vs. 84%, p < 0.001) were significantly less frequent at relapse than initial episode. Although 80% (35/44) of the patients achieved favorable long-term outcomes (modified Rankin Scale score, 0-2), only 61% (27/44) returned to their previous work or school life.

CONCLUSION:

Anti-NMDARE can relapse with milder and more limited symptoms than those of initial episode, and some patients did not return to their previous activities even after achieving a neurologically favorable outcome.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Discinesias / Encefalite Antirreceptor de N-Metil-D-Aspartato Tipo de estudo: Diagnostic_studies / Qualitative_research Limite: Humans Idioma: En Revista: J Neurol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Discinesias / Encefalite Antirreceptor de N-Metil-D-Aspartato Tipo de estudo: Diagnostic_studies / Qualitative_research Limite: Humans Idioma: En Revista: J Neurol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão